Shares of Actuate Therapeutics, Inc. (NASDAQ:ACTU - Get Free Report) dropped 4.6% during trading on Wednesday . The company traded as low as $6.23 and last traded at $6.44. Approximately 52,973 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 51,906 shares. The stock had previously closed at $6.75.
Analyst Upgrades and Downgrades
Several research analysts have commented on ACTU shares. HC Wainwright boosted their target price on Actuate Therapeutics to $20.00 and gave the stock a "buy" rating in a research note on Tuesday, June 3rd. Craig Hallum started coverage on Actuate Therapeutics in a research note on Tuesday, April 22nd. They set a "buy" rating and a $21.00 target price for the company.
Read Our Latest Stock Report on Actuate Therapeutics
Actuate Therapeutics Stock Up 2.4%
The company has a fifty day moving average of $9.14 and a 200 day moving average of $8.32.
Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.06).
Institutional Investors Weigh In On Actuate Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of ACTU. BIOS Capital Management LP purchased a new stake in shares of Actuate Therapeutics during the 4th quarter valued at $78,753,000. Voss Capital LP increased its position in shares of Actuate Therapeutics by 157.7% during the 1st quarter. Voss Capital LP now owns 142,381 shares of the company's stock valued at $964,000 after purchasing an additional 87,135 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Actuate Therapeutics during the 4th quarter valued at $130,000. Sigma Planning Corp purchased a new stake in shares of Actuate Therapeutics during the 4th quarter valued at $128,000. Finally, Goldman Sachs Group Inc. increased its position in shares of Actuate Therapeutics by 98.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company's stock valued at $151,000 after purchasing an additional 11,105 shares during the last quarter.
About Actuate Therapeutics
(
Get Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Recommended Stories
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
